Overview

Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Status:
Recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of anti Tim3/CD123 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Xuzhou Medical University